Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis

OBJECTIVE To determine whether the presence of anticardiolipin antibodies is a risk factor for ischemic stroke and venous thrombosis in healthy adult men. DESIGN A nested, case-control study in a prospective cohort. SETTING A nationwide study of physicians. PARTICIPANTS The study sample was drawn from the Physicians' Health Study, a randomized, double-blind, placebo-controlled trial of aspirin and beta-carotene in 22,071 male physicians. At entry, 68% of the participants submitted plasma samples that were subsequently frozen at -80 degrees C. During 60.2 months of follow-up, follow-up for nonfatal outcomes was 99.7% complete and ascertainment of fatal outcomes was 100% complete. We identified men with documented ischemic stroke, deep venous thrombosis of the leg, or pulmonary embolus and for whom a plasma sample was available. A control was matched by age, smoking history, and length of follow-up to each of the 100 patients with ischemic stroke and the 90 patients with deep venous thrombosis or pulmonary embolus. MEASUREMENTS Plasma samples were assessed for IgG anticardiolipin antibodies by enzyme-linked immunosorbent assay. The mean anticardiolipin antibody titers of the case patients in the two diagnostic groups (ischemic stroke; venous thrombosis or pulmonary embolus) were compared with those of the control groups, and relative risks were calculated for patients in increasing percentile categories of anticardiolipin antibodies by conditional logistic regression. RESULTS The anticardiolipin antibody titers were higher in case patients with deep venous thrombosis and pulmonary embolus than in their matched controls (P = 0.01). Persons with anticardiolipin antibody titers above the 95th percentile had a relative risk for developing deep venous thrombosis or pulmonary embolus of 5.3 (95% CI, 1.55 to 18.3; P = 0.01). The anticardiolipin antibody titers in case patients with ischemic stroke and controls were not significantly different (P > 0.2), and no clear trend of higher risks among those with elevated levels of anticardiolipin antibodies was observed. CONCLUSION An anticardiolipin antibody level above the 95th percentile is an important risk factor for deep venous thrombosis or pulmonary embolus but not for ischemic stroke in healthy adult men.

[1]  S. Santoro,et al.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. , 1990, Annals of internal medicine.

[2]  G. Hughes,et al.  Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. , 1988, Annals of the rheumatic diseases.

[3]  A. Hamsten,et al.  ANTIBODIES TO CARDIOLIPIN IN YOUNG SURVIVORS OF MYOCARDIAL INFARCTION: AN ASSOCIATION WITH RECURRENT CARDIOVASCULAR EVENTS , 1986, The Lancet.

[4]  D. Alarcón-Segovia,et al.  Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to reactivity of anticardiolipin antibody with thrombomodulin. , 1989, The Journal of rheumatology.

[5]  D. Bell,et al.  Cerebral ischemic events associated with endocarditis, retinal vascular disease, and lupus anticoagulant. , 1991, The American journal of medicine.

[6]  J. Vermylen,et al.  ARTERIAL THROMBOSIS, INTRAUTERINE DEATH AND "LUPUS" ANTICOAGULANT: DETECTION OF IMMUNOGLOBULIN INTERFERING WITH PROSTACYCLIN FORMATION , 1981, The Lancet.

[7]  M. Lockshin.  Antiphospholipid antibody and antiphospholipid antibody syndrome , 1991, Current opinion in rheumatology.

[8]  G. Hughes,et al.  Antiphospholipid Anti-Bodies—Autoantibodies with a Difference , 1988 .

[9]  D. Male,et al.  Anti-phospholipid antibodies in syphilis and a thrombotic subset of SLE: distinct profiles of epitope specificity. , 1985, Clinical and experimental immunology.

[10]  G. Hughes,et al.  Myocardial infarction in systemic lupus erythematosus and "lupus-like" disease. , 1986, Arthritis and rheumatism.

[11]  K. Kalunian,et al.  Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. , 1988, The American journal of medicine.

[12]  L. Kater,et al.  Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. , 1986, Arthritis and rheumatism.

[13]  A. Todd-Pokropek,et al.  The Relationship of Anti‐DNA Antibody Idiotypes and Anti‐Cardiolipin Antibodies to Disease Activity in Systemic Lupus Erythematosus , 1986, Medicine.

[14]  G. Hughes,et al.  Myocardial infarction and antiphospholipid antibodies in SLE and related disorders. , 1989, The Quarterly journal of medicine.

[15]  P. Jungers,et al.  Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. , 1987, The Journal of rheumatology.

[16]  G. Hughes,et al.  Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. , 1987, Annals of the rheumatic diseases.

[17]  B. Coull,et al.  Antiphospholipid antibodies, prethrombotic states, and stroke. , 1990, Stroke.

[18]  G. Hughes,et al.  Crossreactivity of antiphospholipid antibodies. , 1985, Journal of clinical & laboratory immunology.

[19]  O. Nived,et al.  Anticardiolipin antibodies in patients with systemic lupus erythematosus. , 1987, Arthritis and rheumatism.

[20]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Hughes,et al.  Aortic occlusion in systemic lupus erythematosus associated with antiphospholipid antibodies. , 1987, Annals of the rheumatic diseases.

[22]  G. Hughes,et al.  Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. , 1986, Archives of internal medicine.

[23]  S. Brink,et al.  The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus. , 1989, British journal of rheumatology.

[24]  R. de Caterina,et al.  Prevalence of anticardiolipin antibodies in coronary artery disease. , 1990, The American journal of cardiology.

[25]  M. Donaldson,et al.  Screening for hypercoagulable states in vascular surgical practice: a preliminary study. , 1990, Journal of vascular surgery.

[26]  K. Welch,et al.  The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. , 1987, Archives of neurology.

[27]  J. Smith,et al.  Anticardiolipin antibodies in patients with rheumatic diseases. , 1987, Arthritis and rheumatism.

[28]  H. Luthra,et al.  Occlusive retinal vascular disease in systemic lupus erythematosus. , 1984, The Journal of rheumatology.

[29]  C. Mackworth-Young,et al.  ANTICARDIOLIPIN ANTIBODIES: DETECTION BY RADIOIMMUNOASSAY AND ASSOCIATION WITH THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS , 1983, The Lancet.

[30]  P. D. de Groot,et al.  Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. , 1989, Annals of the rheumatic diseases.

[31]  G. Hughes,et al.  The “Primary” Antiphospholipid Syndrome: Major Clinical and Serological Features , 1989, Medicine.

[32]  F. Strauss,et al.  Anti-cardiolipin antibodies in ischaemic heart disease. , 1988, Clinical and experimental immunology.

[33]  D. Singer,et al.  Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.

[34]  F. Lundin,et al.  Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. , 1991, American journal of epidemiology.

[35]  M. Lockshin,et al.  Antiphospholipid antibody syndrome: immunologic and clinical aspects. , 1990, Seminars in arthritis and rheumatism.

[36]  G. Hughes,et al.  Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. , 1983, British medical journal.

[37]  H. Arnesen,et al.  Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke , 1992, The Lancet.

[38]  W. Coon.  Risk factors in pulmonary embolism. , 1976, Surgery, gynecology & obstetrics.

[39]  J. Sánchez-Guerrero,et al.  Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. , 1990, The Journal of rheumatology.

[40]  N. Simonian,et al.  Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. , 1989, Stroke.

[41]  G. Hughes,et al.  Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. , 1989, The American journal of medicine.

[42]  J. Mccrea,et al.  Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. , 1985, Clinical and experimental immunology.

[43]  J. Sánchez-Guerrero,et al.  Antiphospholipid Antibodies and the Antiphospholipid Syndrome in Systemic Lupus Erythematosus A Prospective Analysis of 500 Consecutive Patients , 1989, Medicine.

[44]  J. Klippel,et al.  IgG and IgM anticardiolipin antibodies in patients with lupus with anticardiolipin antibody associated clinical syndromes. , 1988, The Journal of rheumatology.

[45]  G. Hughes,et al.  Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome. , 1989, Annals of the rheumatic diseases.